Longevity & AgingChemo-Free Triple Drug Combo Shows Durable Responses in Resistant Lung Cancer
A phase II clinical trial tested a chemotherapy-free three-drug combination — amivantamab, lazertinib, and bevacizumab — in patients with EGFR-mutant advanced non-small cell lung cancer who stopped responding to standard targeted therapy. The combination achieved a 39% best overall response rate and a median progression-free survival of nearly 11 months, among the longest reported in this resistant setting. Median overall survival reached 19.9 months. The triplet works by simultaneously blocking three cancer-driving pathways: EGFR, MET, and the blood vessel growth factor VEGF. While results are encouraging, the trial lacked a control group, making it hard to know how much of the benefit reflects the treatment versus patient selection. Larger randomized trials are needed to confirm these findings.
